研究单位：[1]Responsible Party: Chia Tai Tianqing Pharmaceutical Group Co.,Ltd.[2]First People's Hospital of Yunnan Province Kunming,Yunnan,China,650100[3]The Second Affiliated Hospital of Kunming Medical University Kunming,Yunnan,China[4]Affiliated to Zhejiang University School of Medicine,Sir Run Run Shaw Hospital Hangzhou,Zhejiang,China[5]Tianjin People's Hospital Tianjin,Tianjin,China,300000[6]General Hospital of Tianjin Medical University Tianjin,Tianjin,China[7]Tianjin Medical University Cancer Institute and Hospital Tianjin,Tianjin,China
研究目的：
The objective of this study is to evaluate the efficacy of TQ-B3525 in patients with relapsed / refractory follicular lymphoma.
